The status of serum cortisol before and after treatment of schizophrenia and its correlation to disease severity and improvement: A longitudinal study. (November 2021)
- Record Type:
- Journal Article
- Title:
- The status of serum cortisol before and after treatment of schizophrenia and its correlation to disease severity and improvement: A longitudinal study. (November 2021)
- Main Title:
- The status of serum cortisol before and after treatment of schizophrenia and its correlation to disease severity and improvement: A longitudinal study
- Authors:
- Woldesenbet, Yohannes Markos
Alenko, Arefayne
Bukata, Iyasu Tadesse
Gedefaw, Lealem
Fikru, Chaltu - Abstract:
- Background: Hypothalamic–pituitary–adrenal axis functioning, with cortisol as its major output hormone, has been presumed to play a key role in the development of psychopathology of schizophrenia. Objective: We examined the association of serum cortisol with disease severity and improvement in schizophrenia patients in Jimma, Ethiopia. Method: A total of 34 newly diagnosed schizophrenics were included in this study. Data on demographic, behavioral, clinical state, serum cholesterol level, and antipsychotic usage were obtained at baseline and after 8 weeks. The Positive and Negative Syndrome Scale was used to assess psychotic symptoms severity. A paired sample t -test was used to compare baseline and post-treatment values. Linear regression was used to assess associations. Result: Post-treatment serum cortisol level was significantly lower than its baseline value ( p = 0.001). There was also a significant positive and negative psychotic symptoms decrease after treatment (baseline positive psychotic vs post-treatment positive psychotic symptoms: t (33) = 6.24 (95% confidence interval = 7.03, 13.84, p = 0.000) and (baseline negative psychotic vs post-treatment negative psychotic symptoms: t (33) = 4.21 (95% confidence interval = 3.82, 10.99, p = 0.000). At baseline, neither positive nor negative subscore on the Positive and Negative Syndrome Scale showed an association with serum cortisol level ( B = −0.016, p = 0.794 and B = −0.032, p = 0.594). However, serum cortisol levelBackground: Hypothalamic–pituitary–adrenal axis functioning, with cortisol as its major output hormone, has been presumed to play a key role in the development of psychopathology of schizophrenia. Objective: We examined the association of serum cortisol with disease severity and improvement in schizophrenia patients in Jimma, Ethiopia. Method: A total of 34 newly diagnosed schizophrenics were included in this study. Data on demographic, behavioral, clinical state, serum cholesterol level, and antipsychotic usage were obtained at baseline and after 8 weeks. The Positive and Negative Syndrome Scale was used to assess psychotic symptoms severity. A paired sample t -test was used to compare baseline and post-treatment values. Linear regression was used to assess associations. Result: Post-treatment serum cortisol level was significantly lower than its baseline value ( p = 0.001). There was also a significant positive and negative psychotic symptoms decrease after treatment (baseline positive psychotic vs post-treatment positive psychotic symptoms: t (33) = 6.24 (95% confidence interval = 7.03, 13.84, p = 0.000) and (baseline negative psychotic vs post-treatment negative psychotic symptoms: t (33) = 4.21 (95% confidence interval = 3.82, 10.99, p = 0.000). At baseline, neither positive nor negative subscore on the Positive and Negative Syndrome Scale showed an association with serum cortisol level ( B = −0.016, p = 0.794 and B = −0.032, p = 0.594). However, serum cortisol level showed strong associations with post-treatment positive sub scores and negative sub scores ( B = 0.167, p = 0.007) and ( B = 0.144, p = 0.010) on the Positive and Negative Syndrome Scale. Conclusion: We found a significant decrease in serum cortisol level after antipsychotics treatment and that was associated with improvement in psychotic symptoms in schizophrenics in Jimma, Ethiopia. … (more)
- Is Part Of:
- SAGE open medicine. Volume 9(2021)
- Journal:
- SAGE open medicine
- Issue:
- Volume 9(2021)
- Issue Display:
- Volume 9, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 9
- Issue:
- 2021
- Issue Sort Value:
- 2021-0009-2021-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-11
- Subjects:
- Hypothalamic–pituitary–adrenal axis -- schizophrenia -- association -- Ethiopia
Medicine -- Periodicals
610.5 - Journal URLs:
- http://smo.sagepub.com/ ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.1177/20503121211056216 ↗
- Languages:
- English
- ISSNs:
- 2050-3121
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 18248.xml